2008
An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast*
Gottlieb A, Strober B, Krueger J, Rohane P, Zeldis J, Hu C, Kipnis C. An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast*. Current Medical Research And Opinion 2008, 24: 1529-1538. PMID: 18419879, DOI: 10.1185/030079908x301866.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAnti-Inflammatory AgentsBiopsy, NeedleConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleEpidermisFemaleFollow-Up StudiesHumansImmunohistochemistryMaleMiddle AgedPhosphodiesterase 4 InhibitorsPilot ProjectsPsoriasisSeverity of Illness IndexThalidomideTreatment OutcomeConceptsSevere plaque-type psoriasisPlaque-type psoriasisAdverse eventsTumor necrosis factor-alpha levelsAbnormal laboratory test resultsStatic Physician's Global AssessmentOpen-label pilot studyNecrosis factor-alpha levelsGlobal assessmentSingle-arm pilot studyOral anti-inflammatory agentsPilot studyClinical efficacy scoresMultiple inflammatory factorsPhysician global assessmentLesional skin biopsiesPathogenesis of psoriasisBody surface areaAnti-inflammatory agentsPhosphodiesterase 4 inhibitorCD11c cellsInflammatory markersPASI scorePsoriasis AreaInflammatory factors
2005
Etanercept does not effectively treat moderate to severe alopecia areata: An open-label study
Strober B, Siu K, Alexis A, Kim G, Washenik K, Sinha A, Shupack J. Etanercept does not effectively treat moderate to severe alopecia areata: An open-label study. Journal Of The American Academy Of Dermatology 2005, 52: 1082-1084. PMID: 15928633, DOI: 10.1016/j.jaad.2005.03.039.Peer-Reviewed Original ResearchConceptsSevere alopecia areataAlopecia areataAlopecia totalisAlopecia universalisOpen-label pilot studyEfficacy of etanerceptOpen-label studyTNF-alpha inhibitorsPrimary outcome measureEnd of treatmentAlopecia ToolHair regrowthOutcome measuresEtanerceptHealthy adultsAreataContinuous treatmentPilot studySignificant regrowthTotalisTreatmentUniversalisSubjectsSeverityWeeks